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Abstract
Glutamate transporter (GT) plays a major role in the mechanisms of glutamate homeostasis. Can
this transporter system be a therapeutic target for glutamate-mediated neurological disorders? In
January's edition of Nature, Rothstein et al (2005) reports that the most commonly used class of
antibiotics (β-lactam antibiotics) such as ceftriaxone promoted the expression of GLT1 and
demonstrated a functional role in both in vitro and in vivo models of glutamate neurotocixity. These
findings indicate that positive promoters of GT expression may have a unique role in
neuroprotection through regulating GT expression. This is also encouraging in search for new
pharmacological tools for pain management.
Glutamate is the major excitatory amino acid neurotrans-
mitter that plays an important role in many physiological
functions. Maintaining a physiological range of extracel-
lular glutamate concentration is key to preventing gluta-
mate over-excitation and neurotoxicity that could occur
under a variety of pathological conditions. Regulating
extracellular glutamate is primarily carried out by an effi-
cient, high-capacity glutamate transporter (GT) system,
because clearance of extracellular glutamate via glutamate
metabolism or diffusion is negligible. To date, at least five
cell membrane GT proteins have been cloned [2,3]. GT is
labeled by a common name 'excitatory amino acid trans-
porter' (e.g., EAAT1). Among cell membrane GT, EAAT1
(GLAST), EAAT2 (GLT1), and EAAT3 (EAAC1) are partic-
ularly relevant to the regulation of glutamate uptake in
broad CNS regions. EAAC1 is generally considered as a
neuronal GT, whereas GLAST and GLT1 are primarily
astroglial GT, although both GLAST and GLT1 also have
been located in neuronal cells during the developmental
stage [2,3].
Glutamate has a dual role both as an excitatory neuro-
transmitter essential for physiological functions and a
neurotoxic mediator contributory to pathological proc-
esses. Since the homeostasis of extracellular glutamate
concentration is critically regulated by neuronal and glial
GT, reduced GT expression and/or function would be
expected to increase extracellular glutamate concentration
with subsequent excessive activation of glutamate recep-
tors and excitotoxicity. Indeed, a large number of studies
have shown the detrimental effects from reduced GT
expression and function on the pathogenesis of neurolog-
ical disorders including brain ischemia, epilepsy, spinal
cord injury, amyotrophic lateral sclerosis, AIDS neuropa-
thy, and Alzheimer's disease.
Given the well-documented role of the glutamatergic sys-
tem in the mechanisms of pathological pain, it is not sur-
prising that regulation of GT also has been implicated in
the central mechanisms of nociceptive processing, such as
that following the hindpaw formalin injection or the
application of exogenous NMDA or protaglandins in rats
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[4,5]. A series of recent experiments have demonstrated
that the expression of spinal GT was altered following
peripheral nerve injury and contributed to neuropathic
pain behaviors in rats [6]. The altered GT expression after
nerve injury was mediated, at least in part, through a tyro-
sine kinase receptor (TrkB) and intracellular mitogen-acti-
vated protein kinases. Moreover, peripheral nerve injury
significantly reduced spinal glutamate uptake activity,
supporting a functional role of spinal GT, via regulating
regional glutamate homeostasis, in the mechanisms of
nerve injury-induced neuropathic pain behaviors [6]. Of
interest is that recent studies also have demonstrated that
chronic morphine administration regulated the spinal GT
expression, which contributed to the mechanisms of mor-
phine tolerance and associated neuronal apoptosis and
hyperalgesia in rats [7-9]. Since neuropathic pain and opi-
oid tolerance have been shown to share a common gluta-
matergic mechanism [10], these findings indicate that
regulation of the GT expression and function would be an
important approach to preventing and reversing gluta-
mate over-excitation and neurotoxocity associated with
the mechanisms of neuropathic pain and opioid toler-
ance.
Despite a positive regulatory role of certain compounds
such as riluzole and MS-153 in GT function in pre-clinical
studies of neuropathic pain and morphine tolerance [6-
9], the exact mechanisms of GT regulation remain
unclear. A recent article by Rothstein et al [1] reports that
the most commonly used class of antibiotics (β-lactam
antibiotics) such as ceftriaxone promoted the expression
of GLT1 and demonstrated a functional role in both in
vitro and in vivo models of glutamate neurotocixity. These
findings indicate that positive promoters of GT expression
may have a unique role in neuroprotection through regu-
lating GT expression. The regulatory role of β-lactam anti-
biotics in promoting GT expression appears to be
selective, because other classes of antibiotics such as van-
comycin were ineffective [1]. The results from this study
are encouraging in search for new pharmacological tools
for neuroprotection and pain management. A potential
issue concerning such an approach, however, is the devel-
opment of antibiotic-resistant bacteria associated with its
application, making it less practical to directly use an anti-
biotic therapy for managing neuropathic pain, opioid tol-
erance, and neurological disorders. Therefore, it may be
expected that future studies would explore the genomic
regulation of GT expression promoted by β-lactam antibi-
otics in order to elucidate the regulatory pathway(s) of GT
expression at the molecular level.
In contrast to antagonism of glutamate receptors, a dis-
tinct advantage of regulating GT expression and activity is
the possibility of minimizing the pathological impact
from a glutamate overload while retaining the physiolog-
ical role of glutamate. A similar approach is used in devel-
oping anti-psychiatric drugs, including broad and
selective monoamine reuptake agents, and has yielded
rather positive outcomes in the treatment of psychiatric
disorders. Extensive research is under way to explore the
cellular and molecular mechanisms of GT expression and
function in relation to the pathogenesis of neuropathic
pain. In addition, studies on the role of GT regulation in
opioid tolerance and dependence may provide new
insights into the cellular mechanisms of substance abuse,
an emerging issue associated with clinical opioid therapy.
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